Publications by authors named "Richard Went"

Claim this Profile
V
Venetoclax is an option in B-cell prolymphocytic leukaemia following progression on B-cell receptor pathway inhibitors.
Nikila Patil, Richard G Went

Br J Haematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.
Toby A Eyre, Christopher P Fox, Ali Boden, Adrian Bloor, Moez Dungawalla, Richard Went

Br J Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
Toby A Eyre, Christopher P Fox, Paneesha Shankara, Richard Went, Anna H Schuh

Br J Haematol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system prophylaxis in patients with diffuse large B cell lymphoma, are we treating ourselves? A response to the recent BCSH Guideline.
Morag Griffin, Kathryn Goddard, Nicholas Morley, Richard Went, Andrew Fletcher

Br J Haematol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-Fy3 in sickle cell disease: a difficult transfusion problem.
Richard Went, Josh Wright, Robert Webster, Robert Stamps

Br J Haematol· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolated tongue amyloid in a patient with multiple myeloma.
Richard Went, Dominic Chan-Lam, Martin Thornhill

Br J Haematol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis